PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
PRECIGEN, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$6.66+0.28 (+4.31%)
Close on Oct 19, 2026
- Market cap
- $2.76B
- P/E (TTM)
- –
- Dividend yield
- –
PRECIGEN, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $9.68M | $3.93M | $6.23M | – | – | – | – | – | – | – | 100.0% | +146.7% |
| Reportable Segments | – | – | – | $28.36M | $15.90M | $36.74M | $96.17M | $112.90M | $161.66M | – | – | – |
| All Other Segment Adjusted EBITDA | – | – | – | – | – | $10.58M | $4.88M | $30.47M | $59.80M | – | – | – |
| PGEN Therapeutics | – | – | – | – | – | – | $13.57M | $29.64M | $53.18M | – | – | – |
| MBP Titan | – | – | – | – | – | – | $3.91M | $9.94M | $14.34M | – | – | – |
| Trans Ova | – | – | – | – | $90.04M | $71.53M | $70.03M | $75.74M | $80.03M | – | – | – |
| Acto Bio | – | – | – | – | – | $3.05M | $134.00K | $7.52M | $14.11M | – | – | – |
| PGEN Therapeutics | – | – | – | – | – | $5.78M | $13.57M | $29.64M | – | – | – | – |
| Human Biotherapeutics | – | – | – | – | – | $17.81M | $3.71M | $0 | – | – | – | – |
| Exemplar | – | $3.93M | $6.15M | $12.02M | $13.35M | $10.16M | $6.97M | – | – | – | – | – |
| Biopharmaceuticals | – | $0 | $75.00K | $14.89M | $922.00K | $26.58M | $19.17M | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and Service | $7.87M | $3.93M | $6.15M | – | – | – | – | – | – | – | 81.2% | +100.4% |
| Product revenues, net | $3.98M | $422.00K | $840.00K | – | – | – | – | $28.53M | $33.59M | $36.96M | 41.0% | +841.9% |
| Service revenues | $3.89M | $3.50M | $5.31M | – | – | – | – | $52.42M | $50.61M | $43.05M | 40.2% | +11.1% |
| Exemplar | $3.89M | $3.50M | $5.31M | – | – | – | – | – | – | – | 40.2% | +11.1% |
| Papzimeos | $3.41M | $0 | $0 | – | – | – | – | – | – | – | 35.2% | – |
| Exemplar | $562.00K | $422.00K | $840.00K | – | – | – | – | – | – | – | 5.8% | +33.2% |
| Other revenues | – | – | – | – | – | – | – | $2.76M | $1.20M | $1.05M | – | – |
| Collaboration and licensing agreements | – | – | – | – | – | – | $14.06M | $69.54M | $134.62M | $109.87M | – | – |
By region
From the segment and revenue-disaggregation notes of Precigen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.